SpyGlass Pharma Reports Trial of Eye Implant Lowers Pressure by 37%

09:21 AM EDT, 10/19/2026 (MT Newswires) -- SpyGlass Pharma (SGP) reported Monday that four-year trial data for its implanted eye drug delivery system showed that average internal eye pressure dropped 37%, and that 86% of participants stopped using daily prescription eye drops. The biopharmaceutical company said 90% of patients maintained 20/25 or better vision during the four-year period. It also said the trial recorded no drug- or device-related adverse events, and patient vision and eye structures remained stable.